← Back to headlines
Market Panel Favors Novo Nordisk Over Eli Lilly
A "Fast Money" panel has suggested that Novo Nordisk is now a more compelling investment than Eli Lilly, particularly after Novo Nordisk's stock experienced a significant 70% decline. The discussion centered on the relative value and future prospects of the two pharmaceutical giants.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
